May is Multiple Sclerosis (MS) Month. Laboratory and clinical studies related to MS involve about 50 members of The Neuro’s staff. They study the disease in all its aspects and at every stage with the help of the most advanced brain imaging technology and the latest cell biology techniques.

Classified as: Multiple Sclerosis, MS, MS Month, Jack Antel, Doug Arnold, Alyson Fournier, Douglas Arnold, Luke Healy, Tim Kennedy, Christine Tardif, daria trojan, Yves Lapierre, Paul Giacomini, Alex Saveriano, Alexander Saveriano
Category:
Published on: 4 May 2018

The Montreal Neurological Institute and Hospital (The Neuro) is home to Canada’s first multiple sclerosis (MS) clinic, and MS research and treatment has been a major focus at The Neuro for many years. The MS clinic employs a highly specialized staff who have access to the latest research data and methods of treatment. It is a clinic where innovation and progress are paramount.

Classified as: Multiple Sclerosis, Yves Lapierre, Paul Giacomini, Jack Antel, Alyson Fournier, Douglas Arnold, Tim Kennedy, daria trojan
Published on: 1 May 2017

In separate clinical trials, a drug called ocrelizumab has been shown to reduce new attacks in patients with relapsing remitting multiple sclerosis (MS), and new symptom progression in primary progressive MS.

Three studies conducted by an international team of researchers, which included Amit Bar-Or and Douglas Arnold from the Montreal Neurological Institute and Hospital of McGill University, have discovered that ocrelizumab can significantly reduce new attacks in patients with relapsing MS, as well as slow the progression of symptoms caused by primary progressive MS.

Classified as: Research, The Neuro, Amit Bar-Or, MS, health and lifestyle, Douglas Arnold, ocrelizumab
Category:
Published on: 9 Jan 2017

Drug shown to reduce new attacks/symptom progression in some patients

In separate clinical trials, a drug called ocrelizumab has been shown to reduce new attacks in patients with relapsing remitting multiple sclerosis (MS), and new symptom progression in primary progressive MS.

Classified as: MS, ocrelizumab, Amit Bar-Or, Douglas Arnold, Multiple Sclerosis
Published on: 22 Dec 2016

A project led by an MNI researcher has been awarded $6.1 million to study progressive multiple sclerosis.

The International Progressive MS Alliance has awarded three $6.1 million Collaborative Network Award grants for a total investment of $18.4 million toward accelerating the pace of progressive MS research. More than 2.3 million people worldwide live with MS and more than one million of those living with the disease have progressive MS.

Classified as: Multiple Sclerosis, MS, Progressive MS, Douglas Arnold
Published on: 20 Sep 2016

May 2016 - Multiple Sclerosis Awareness Month

 

Multiple sclerosis treatment and research has long been a focus at the Montreal Neurological Institute and Hospital, known simply as The Neuro, an illustrious member of McGill University and the McGill University Health Centre. Indeed, The Neuro introduced Canada’s first MS clinic. The clinic’s highly specialized staff employs the latest research data and treatment methods in a clinical atmosphere of innovation and progress.

Classified as: Multiple Sclerosis, Research, MS, neuroscience, Yves Lapierre, Paul Giacomini, Amit Bar-Or, Jack Antel, Alyson Fournier, Douglas Arnold, Tim Kennedy, daria trojan
Category:
Published on: 2 May 2016

The Montreal Neurological Institute and Hospital – The Neuro at McGill University and the MUHC has Canada’s oldest MS clinic but is always innovating - striving for progress and better treatments for patients.

What’s new in MS at The Neuro

Classified as: Multiple Sclerosis, neuroscience, Montreal Neurological Institute and Hospital, The Neuro, mcgill faculty of medicine research, Neuro Giving, Alyson Fournier, Douglas Arnold, Tim Kennedy, daria trojan, Yves Lapierre, Paul Giacomini, Amit Bar-Or, Jack Antel
Category:
Published on: 7 May 2015
Back to top